[DOI] [PMC free article] [PubMed] [Google Scholar] Nilsson 2005 Nilsson M, Norberg B, Hultdin J, Sandstrom H, Westman G, Lokk J
To be clear, this isnt an adverse effect specific to Ozempic or any GLP-1 agonist drug
As discussed in our previous blog, these miracle drugs for treating obesity and type-2 diabetes are in high demand, with limited supply and only a few manufacturing companies competing for the market share
Mochi Health: Specific Patient Profiles Who Should Avoid It (and Why) Mochi Health: Specific Patient Profiles Who Should Avoid It At a glance Service type / GLP-1 telehealth (insurance + cash-pay) Primary medications offered / Semaglutide, tirzepatide, compounded GLP-1 agents Monthly membership fee / Approximately $99/month (as of early 2025) Insurance accepted / Yes, select plans BBB accreditation / Not accredited as of January 2025 FDA-cleared drugs available / Yes (Wegovy, Ozempic, Mounjaro, Zepbound) Key contraindicated profiles / MTC/MEN2 history, active eating disorder, pregnancy, severe renal/hepatic disease LegitScript status / Not certified as of January 2025 Prescriber type / Physician and nurse practitioner-staffed asynchronous + synchronous visits Compounded GLP-1 risk / Compounded semaglutide from 503A/503B pharmacies carries FDA safety warnings What Is Mochi Health and How Does It Work
How To Use Acetyl L-Carnitine by Alien
